Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Contineum Therapeutics, Inc. Class A Common Stock at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Biotechnology company based in US with a market capitalization of $519.7M. Free cash flow was negative at -$55.5M. This page tracks CTNM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 41 employees · IPO Apr 5, 2024
Valuation
Valuation & price
$13.72as of May 17, 2026· -16.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.99
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$519.7M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$55.5M
Free cash flow (USD)
-$254.6M
Net debt
Net cash position
7.1%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2021 → 2025
Free cash flow by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
6
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 5, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 13, 2026Filing
Corporate Presentation
- Insider sellJul 10, 2026Filing
Insider Sell $17K · 10b5-1 PlanLorrain Daniel S. · Chief Scientific Officer · $16.6K
- Insider sellJul 8, 2026Filing
Insider Sell $40K · 10b5-1 PlanStengone Carmine N. · Director, CEO and President · $40K
- Insider sellJul 2, 2026Filing
Insider Sell $595K · 10b5-1 PlanLorrain Daniel S. · Chief Scientific Officer · $594.6K
- Insider sellJul 1, 2026Filing
Insider Sell $160K · 10b5-1 PlanStengone Carmine N. · Director, CEO and President · $160.1K
- Insider sellJul 1, 2026Filing
Insider Sell $174K · 10b5-1 PlanWatkins Tim · CMO & Head of Development · $173.6K
- 8-K eventJun 26, 2026Filing
Annual Meeting Results
- Insider sellJun 1, 2026Filing
Insider Sell $55K · 10b5-1 PlanLorrain Daniel S. · Chief Scientific Officer · $54.9K
- 8-K eventMay 5, 2026Filing
Earnings Release
- Quarterly reportMay 5, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Contineum Therapeutics, Inc. Class A Common Stock's market cap?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market capitalization of $519.7M.
What is CTNM's P/E ratio?
A meaningful P/E ratio is not available for CTNM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CTNM's price-to-book (P/B) ratio?
CTNM trades at 1.99 times book value per share.
Are insiders buying CTNM stock?
SEC Form 4 filings show no open-market insider buys at Contineum Therapeutics, Inc. Class A Common Stock in the last 90 days (6 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.